{"url_path":"/sec/dmaa/8-k/2026-07-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-079678-index.html","accession_number":"0001213900-26-079678","cik":"0002028614","ticker":"DMAA","issuer_name":"Drugs Made In America Acquisition Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-079678-index.html","primary_entity_key":"0002028614","primary_entity_name":"Drugs Made In America Acquisition Corp."},"word_count":125,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) **Exhibits.**\n\n \n\n**Exhibit No.**\n \n**Description**\n\n2.1\n \n[Omnibus Amendment No. 3 to the Merger Agreement†](ea029846101ex2-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*† Certain schedules and exhibits to\nthis Exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby agrees to furnish a copy of any omitted\nschedule or exhibit to the SEC upon request.*\n\n \n\n3\n\n \n\n  \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n**DRUGS MADE IN AMERICA ACQUISITION CORP.**\n\n \n \n \n\nDate: July 20, 2026\n \n\n \n \n\nBy:\n/s/ Roger E. Bendelac\n \n\nName: \nRoger E. Bendelac\n \n\nTitle:\nChief Executive Officer\n \n\n \n\n4"}